Expres2ion Biotech Holding Stock Profit Margin
| EXPRS2 Stock | SEK 20.85 1.87 9.85% |
ExpreS2ion Biotech Holding fundamentals help investors to digest information that contributes to ExpreS2ion Biotech's financial success or failures. It also enables traders to predict the movement of ExpreS2ion Stock. The fundamental analysis module provides a way to measure ExpreS2ion Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ExpreS2ion Biotech stock.
ExpreS2ion |
ExpreS2ion Biotech Holding Company Profit Margin Analysis
ExpreS2ion Biotech's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, ExpreS2ion Biotech Holding has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The profit margin for all Sweden stocks is 100.0% lower than that of the firm.
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
ExpreS2ion Fundamentals
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (20.75) % | |||
| Current Valuation | 361.15 M | |||
| Shares Outstanding | 37.15 M | |||
| Shares Owned By Institutions | 1.75 % | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 55.94 X | |||
| Revenue | 12.23 M | |||
| Gross Profit | 1.07 M | |||
| EBITDA | (45.5 M) | |||
| Net Income | (43.92 M) | |||
| Cash And Equivalents | 10.14 M | |||
| Cash Per Share | 0.75 X | |||
| Total Debt | 3.48 M | |||
| Debt To Equity | 10.40 % | |||
| Current Ratio | 2.62 X | |||
| Book Value Per Share | 2.75 X | |||
| Cash Flow From Operations | (45.65 M) | |||
| Earnings Per Share | (1.55) X | |||
| Number Of Employees | 14 | |||
| Beta | 1.25 | |||
| Market Capitalization | 487.85 M | |||
| Total Asset | 151.96 M | |||
| Z Score | 84.0 | |||
| Net Asset | 151.96 M |
About ExpreS2ion Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ExpreS2ion Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ExpreS2ion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ExpreS2ion Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in ExpreS2ion Stock
ExpreS2ion Biotech financial ratios help investors to determine whether ExpreS2ion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ExpreS2ion with respect to the benefits of owning ExpreS2ion Biotech security.